1 Fioretto P, "Residual microvascular risk in diabetes : unmet needs and future directions" 6 : 19-25, 2010
2 Giorgino F, "Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk" 19 : 196-, 2020
3 Thomson SC, "Renal effects of incretin-based diabetes therapies : pre-clinical predictions and clinical trial outcomes" 18 : 28-, 2018
4 Groop PH, "Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction : the randomized MARLINA-T2D trial" 19 : 1610-1619, 2017
5 de Boer IH, "Executive summary of the 2020KDIGO diabetes management in CKD guideline : evidencebased advances in monitoring and treatment" 98 : 839-848, 2020
6 Wheeler DC, "Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial" 9 : 22-31, 2021
7 원종철, "Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status" 대한당뇨병학회 42 (42): 415-424, 2018
8 배재현, "Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis" 대한내분비학회 36 (36): 388-400, 2021
9 Rangaswami J, "Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease : a scientific statement from the American Heart Association" 142 : e265-86, 2020
10 Perkovic V, "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy" 380 : 2295-2306, 2019
1 Fioretto P, "Residual microvascular risk in diabetes : unmet needs and future directions" 6 : 19-25, 2010
2 Giorgino F, "Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk" 19 : 196-, 2020
3 Thomson SC, "Renal effects of incretin-based diabetes therapies : pre-clinical predictions and clinical trial outcomes" 18 : 28-, 2018
4 Groop PH, "Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction : the randomized MARLINA-T2D trial" 19 : 1610-1619, 2017
5 de Boer IH, "Executive summary of the 2020KDIGO diabetes management in CKD guideline : evidencebased advances in monitoring and treatment" 98 : 839-848, 2020
6 Wheeler DC, "Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial" 9 : 22-31, 2021
7 원종철, "Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status" 대한당뇨병학회 42 (42): 415-424, 2018
8 배재현, "Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis" 대한내분비학회 36 (36): 388-400, 2021
9 Rangaswami J, "Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease : a scientific statement from the American Heart Association" 142 : e265-86, 2020
10 Perkovic V, "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy" 380 : 2295-2306, 2019
11 American Diabetes Association, "9. Pharmacologic approaches to glycemic treatment : standards of medical care in diabetes-2021" 44 (44): S111-24, 2021
12 Cosentino F, "2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD" 41 : 255-323, 2020
국립중앙도서관 "우편 복사 서비스"로 연결 됩니다.
KCI
